Lymphoma, Malignant Clinical Trial
Official title:
Therapy of Nodal Follicular Lymphoma (Grade I/II) Clinical Stage I or II Using Involved Field Radiotherapy in Combination With Rituximab
Combination of involved field radiotherapy for the control of macroscopic disease and CD20 antibody Rituximab for the control of microscopic remainders in other regions in patients with early stage nodal follicular lymphoma /grade I or II). Evaluation of DFSl and toxicity.
The MIR (Mabthera(R) and Involved field Radiation) study is a prospective multicenter trial
combining systemic treatment with the anti CD20 antibody Rituximab (Mabthera(R)) in
combination with involved field radiotherapy (30 - 40 Gy). This trial aims at testing the
combination's efficacy and safety with an accrual of 85 patients.Primary endpoint of the
study is progression free survival. Secondary endpoints are response rate to Rituximab,
complete remission rate at week 18, relapse rate, relapse pattern, relapse free survival,
overall survival, toxicity and quality of life.
More details: Witzens-Harig M, Hensel M, Unterhalt M, Herfarth K. Treatment of limited stage
follicular lymphoma with Rituximab immunotherapy and involved field radiotherapy in a
prospective multicenter Phase II trial-MIR trial. BMC cancer. 2011; 11: 87.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02916979 -
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG
|
Phase 1 | |
| Completed |
NCT00600353 -
Multi-day Doses in Prevention of Nausea and Emesis
|
Phase 2 | |
| Completed |
NCT01432951 -
A Study of Enzastaurin in Chinese Patients With Advanced and/or Metastatic Solid Tumors or Lymphoma
|
Phase 1 | |
| Terminated |
NCT02440685 -
A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT02249429 -
Open-Label, Non Randomized Phase 2 Study With Safety Run-In
|
Phase 2 | |
| Active, not recruiting |
NCT02732275 -
DS-3201b in Participants With Lymphomas
|
Phase 1 | |
| Recruiting |
NCT00619879 -
Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies
|
Phase 3 | |
| Completed |
NCT00146055 -
Low-Intensity Preparation and Allogeneic Transplant in Patients With Cancers of the Blood
|
Phase 2 | |
| Completed |
NCT00741871 -
A Phase 1 Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies
|
Phase 1 | |
| Recruiting |
NCT04947618 -
Efficacy of Patient Management for Lymphoma Diagnosed at Nimes University Hospital From 1999 to 2018. DVR-Lym-Nim
|
||
| Recruiting |
NCT02441972 -
Clinic Study of 18F-Al-NOTA-PRGD2 in Cancer Diagnostics
|
Phase 1 | |
| Completed |
NCT00078637 -
Dosing and Safety Study of E7820 in Patients With a Malignant Solid Tumor or Lymphoma
|
Phase 1 | |
| Withdrawn |
NCT03359733 -
A Study to Evaluate the Effect of Food on the Pharmacokinetics (PK) of TAK-659 in Participants With Advanced Solid Tumor
|
Phase 1 | |
| Completed |
NCT00037791 -
Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia
|
Phase 3 | |
| Completed |
NCT01388335 -
A Drug Interaction Study to Assess the Effect of LY317615 on the Metabolic Pathway of Warfarin
|
Phase 1 |